Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

Inclusion Criteria: * Age ≥ 18 years of age upon entry into screening * History of migraine with or without aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria * ≥ 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening * Subject has provided informed consent prior to initiation of any study-specific activities/procedures. * Must have demonstrated greater than or equal to 75% compliance in Headache Diary usage during the 4-week run-period prior to Day 1 of the open-label treatment phase. Exclusion Criteria: * \> 50 years of age at migraine onset * History of cluster headache or hemiplegic migraine * Inability to differentiate migraine from other headaches * The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior * History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion * Previously received erenumab (Aimovig) * Received anti-CGRP monoclonal antibody within 3 months prior to the CGRP-infusion * Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded. * Female subjects of childbearing potential with a positive pregnancy test during any study visit * Female subject is pregnant or breastfeeding or planning to become pregnant during the study * Evidence of current pregnancy or breastfeeding * Female subject of childbearing potential unwilling to use an acceptable method of effective contraception * Hypertension on the experimental day defined as systolic blood pressure ≥ 150mmHg or diastolic blood pressure ≥ 100mmHg * Hypotension on the experimental day defined as systolic blood pressure \< 90mmHg or diastolic blood pressure \< 50mmHg * Any headache (including migraine) within 24 hours prior to the start of the CGRP-infusion * Intake of any analgesics or migraine-specific medications within 24 hours prior to the start of the CGRP-infusion * Subject likely to not be available to complete all protocol-required study visits or procedures, and/or comply with all required study procedures to the best of the subject and study investigator's knowledge